Avalo Therapeutics (NASDAQ:AVTX) Shares Up 7.9% – Here’s Why

Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares shot up 7.9% on Friday . The company traded as high as $14.82 and last traded at $14.7450. 386,495 shares changed hands during trading, a decline of 64% from the average session volume of 1,087,490 shares. The stock had previously closed at $13.67.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AVTX. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. HC Wainwright cut their price target on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Citizens Jmp cut their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Wolfe Research began coverage on Avalo Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target for the company. Finally, Mizuho raised their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Avalo Therapeutics Trading Up 8.0%

The stock has a market cap of $775.93 million, a price-to-earnings ratio of -2.70 and a beta of 0.83. The stock has a fifty day simple moving average of $15.68 and a 200-day simple moving average of $16.21.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. Sell-side analysts forecast that Avalo Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,457 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the sale, the chief financial officer owned 423 shares of the company’s stock, valued at $5,596.29. This trade represents a 95.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the sale, the insider directly owned 3,622 shares in the company, valued at $65,232.22. This trade represents a 52.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 138,078 shares of company stock valued at $2,501,346 in the last 90 days. 4.46% of the stock is currently owned by insiders.

Institutional Trading of Avalo Therapeutics

Several institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP grew its holdings in shares of Avalo Therapeutics by 806.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after purchasing an additional 510,540 shares in the last quarter. DV Trading LLC acquired a new stake in shares of Avalo Therapeutics during the 1st quarter worth approximately $5,376,000. Glenmede Trust Co. NA grew its holdings in shares of Avalo Therapeutics by 25.8% during the 1st quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock worth $384,000 after purchasing an additional 5,280 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Avalo Therapeutics by 3.5% during the 1st quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after purchasing an additional 21,650 shares in the last quarter. Finally, Exome Asset Management LLC acquired a new stake in shares of Avalo Therapeutics during the 1st quarter worth approximately $2,379,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.